A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia

Radiotherapy and Oncology

Volumn 88, Issue 2, 2008, Pages 258-268

  Liu, Stanley K ^a   Coackley, Carla ^b   Krause, Mechthild ^c   Jalali, Farid ^b   Chan, Norman ^a,b   Bristow, Robert G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Apoptosis; Chemotherapy; DNA repair; Hypoxia; Lung cancer; Molecular inhibitor; PARP; Prostate cancer; Radiosensitivity

Indexed keywords

ABT 888; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYPOXIA; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION;

ANALYSIS OF VARIANCE; ANOXIA; APOPTOSIS; BENZIMIDAZOLES; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA REPAIR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 49149087379     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.04.005     Document Type: Article

References (52)

1. Ma B.B., Bristow R.G., Kim J., and Siu L.L. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 21 (2003) 2760-2776
2. Choudhury A., Cuddihy A., and Bristow R.G. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 16 (2006) 51-58
3. Supiot S., Zhao H., Wiman K., Hill R.P., and Bristow R.G. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol (2008)
4. Tannock I.F., Hill R.P., Bristow R.G., and Harrington L. The basic science of oncology (2005), McGraw-Hill Professional
5. Chan N., Milosevic M., and Bristow R.G. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol 3 (2007) 329-341
6. Sarkaria J.N., and Bristow R.G. Overview of cancer molecular radiobiology. In: Bentzen S.M., Mehta M.P., Harari P.M., and Tome W. (Eds). Radiation oncology advances (2007), Springer 115-131
7. Bristow R.G., Ozcelik H., Jalali F., Chan N., and Vesprini D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol 83 (2007) 220-230
8. Dewhirst M.W., Cao Y., Li C.Y., and Moeller B. Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol 83 (2007) 249-255
9. Seigneuric R., Starmans M.H., Fung G., et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol 83 (2007) 374-382
10. Schreiber V., Dantzer F., Ame J.C., and de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7 (2006) 517-528
11. Jagtap P., and Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4 (2005) 421-440
12. Durkacz B.W., Omidiji O., Gray D.A., and Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 283 (1980) 593-596
13. Ueno A.M., Tanaka O., and Matsudaira H. Inhibition of gamma-ray dose-rate effects by D2O and inhibitors of poly(ADP-ribose) synthetase in cultured mammalian L5178Y cells. Radiat Res 98 (1984) 574-582
14. Thraves P., Mossman K.L., Brennan T., and Dritschilo A. Radiosensitization of human fibroblasts by 3-aminobenzamide: an inhibitor of poly(ADP-ribosylation). Radiat Res 104 (1985) 119-127
15. Kelland L.R., and Tonkin K.S. The effect of 3-aminobenzamide in the radiation response of three human cervix carcinoma xenografts. Radiother Oncol 15 (1989) 363-369
16. Oleinick N.L., and Evans H.H. Poly(ADP-ribose) and the response of cells to ionizing radiation. Radiat Res 101 (1985) 29-46
17. Durkacz B.W., Shall S., and Irwin J. The effect of inhibition of (ADP-ribose)n biosynthesis on DNA repair assayed by the nucleoid technique. Eur J Biochem 121 (1981) 65-69
18. Milam K.M., and Cleaver J.E. Inhibitors of poly(adenosine diphosphate-ribose) synthesis: effect on other metabolic processes. Science 223 (1984) 589-591
19. Banasik M., Komura H., Shimoyama M., and Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267 (1992) 1569-1575
20. Chalmers A.J. Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target. Clin Oncol (R Coll Radiol) 16 (2004) 29-39
21. Schlicker A., Peschke P., Burkle A., Hahn E.W., and Kim J.H. 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int J Radiat Biol 75 (1999) 91-100
22. Brock W.A., Milas L., Bergh S., Lo R., Szabo C., and Mason K.A. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 205 (2004) 155-160
23. Boulton S., Kyle S., and Durkacz B.W. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 20 (1999) 199-203
24. Horsman M.R. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol 34 (1995) 571-587
25. Calabrese C.R., Almassy R., Barton S., et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96 (2004) 56-67
26. Martin-Oliva D., Aguilar-Quesada R., O'Valle F., et al. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 66 (2006) 5744-5756
27. Rajesh M., Mukhopadhyay P., Batkai S., et al. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem Biophys Res Commun 350 (2006) 352-357
28. Rajesh M., Mukhopadhyay P., Godlewski G., et al. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem Biophys Res Commun 350 (2006) 1056-1062
29. Albert J.M., Cao C., Kim K.W., et al. Inhibition of poly(ADP-Ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 13 (2007) 3033-3042
30. Meng A.X., Jalali F., Cuddihy A., et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 76 (2005) 168-176
31. Bromfield G.P., Meng A., Warde P., and Bristow R.G. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 6 (2003) 73-85
32. Bristow R.G., and Hill R.P. Comparison between in vitro radiosensitivity and in vivo radioresponse in murine tumor cell lines. II: In vivo radioresponse following fractionated treatment and in vitro/in vivo correlations. Int J Radiat Oncol Biol Phys 18 (1990) 331-345
33. Donawho C.K., Luo Y., Luo Y., et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13 (2007) 2728-2737
34. Chalmers A., Johnston P., Woodcock M., Joiner M., and Marples B. PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 58 (2004) 410-419
35. Noel G., Godon C., Fernet M., Giocanti N., Megnin-Chanet F., and Favaudon V. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 5 (2006) 564-574
36. Horton J.K., Stefanick D.F., and Wilson S.H. Involvement of poly(ADP-ribose) polymerase activity in regulating Chk1-dependent apoptotic cell death. DNA Repair (Amst) 4 (2005) 1111-1120
37. Wang Z.Q., Stingl L., Morrison C., et al. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 11 (1997) 2347-2358
38. Faulhaber O., and Bristow R.G. Basis of cell kill following clinical radiotherapy. In: Sluyser M. (Ed). Application of apoptosis to cancer treatment (2005), Kluwer-Springer Press, Amsterdam 293-320
39. Hochegger H., Dejsuphong D., Fukushima T., et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J 25 (2006) 1305-1314
40. Wang M., Wu W., Rosidi B., Zhang L., Wang H., and Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 34 (2006) 6170-6182
41. Fan R., Kumaravel T.S., Jalali F., Marrano P., Squire J.A., and Bristow R.G. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res 64 (2004) 8526-8533
42. Haince J.F., Kozlov S., Dawson V.L., et al. ATM signaling network is modulated by a novel PAR-dependent pathway in the early response to DNA damaging agents. J Biol Chem 282 (2007) 16441-16453
43. Ratnam K., and Low J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 13 (2007) 1383-1388
44. 6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 11 (2005) 3402-3409
45. Tentori L., Lacal P.M., Muzi A., et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer 43 (2007) 2124-2133
46. Tentori L., Leonetti C., Scarsella M., et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 20 (2006) 1709-1711
47. Tentori L., and Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52 (2005) 25-33
48. Bindra R.S., Schaffer P.J., Meng A., et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 24 (2004) 8504-8518
49. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
50. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
51. Chan N., Koritzinsky M., Zhao H., et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 68 (2008) 605-614
52. Bristow R.G., and Hill R.P. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8 (2008) 180-192